Synendos Therapeutics Appoints CNS Experts To Advisory Board
Synendos Therapeutics, a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat central nervous system disorders, recently announced the appointment of CNS experts to form its scientific advisory board.
Dr. Andrea Chicca, co-founder and CEO of the Basel, Switzerland-based company, called the move a "significant step for Synendos."
"We are delighted to have brought together a group of highly accomplished and experienced individuals whose knowledge and expertise will provide assured guidance as we advance our novel technology, targeting the brain's natural endocannabinoid system, to address unmet needs in the treatment of anxiety, mood, and stress-related disorders," Chicca said.
The newly formed scientific advisory board includes:
Karl-Heinz Altmann, a professor of pharmaceutical biology and chairman of the department of chemistry and applied biosciences at the Swiss Federal Institute of Technology in Zurich and a co-founder of Tolremo Therapeutics. In addition, he serves on a number of scientific advisory boards and as a consultant to various pharmaceutical companies.
Anahita Bassir Nia, an addiction psychiatrist and assistant professor of psychiatry at Yale School of Medicine, Connecticut, USA, whose primary focus is on the endocannabinoid system in relation to stress, trauma and substance use disorders.
Graeme Bilbe, who is involved in advisory roles to public health institutions, universities and commercial organizations. Bilbe is a former research and development director and current scientific advisor at the Drugs for Neglected Diseases initiative.
Jürg Gertsch, a deputy and co-director of the Institute of Biochemistry and Molecular Medicine at the University of Bern and a full professor of biochemistry and pharmaceutical biology.
Kirsten Müller-Vah, a …